Cargando…
Hydroxychloroquine/lopinavir/ritonavir: Drug ineffectiveness following off-label use in COVID-19 infection: case report
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9073465/ http://dx.doi.org/10.1007/s40278-022-14629-0 |
Ejemplares similares
-
Hydroxychloroquine/lopinavir/ritonavir: Bradycardia and off-label-use: case report
Publicado: (2021) -
Hydroxychloroquine/lopinavir/ritonavir: Lack of efficacy following off-label use: case report
Publicado: (2022) -
Hydroxychloroquine/lopinavir/ritonavir/tocilizumab: Lack of efficacy following off label use: case report
Publicado: (2022) -
Hydroxychloroquine/lopinavir/ritonavir: Guillain-Barre-syndrome and off-label-use: case report
Publicado: (2021) -
Hydroxychloroquine/lopinavir/ritonavir: Lack of efficacy and off label use: 3 case reports
Publicado: (2022)